Parsons James T. - 02 Jan 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Director
Signature: /s/ Amy E. Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 02 Jan 2025
Net transactions value: +$84,997
Form type: 4
Filing time: 03 Jan 2025, 16:46:35 UTC
Previous filing: 03 Jun 2024
Next filing: 03 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAC	Voting Common Shares, no par value per share	Award	$84,997	+15,917	+27%	$5.34	75,854	02 Jan 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+4,287		$0.000000	4,287	02 Jan 2025	Common Shares	4,287	$5.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.
F2	Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.
F3	Vests in two nearly equal installments on each of March 1, 2025 and June 1, 2025.